抗中性粒细胞胞质抗体相关性肾血管炎肾移植后的结局
该多中心回顾性研究比较了206例AAV-GN患者与412例匹配对照在2005至2023年间的肾移植后结局。结果显示两组短期结局相似,但AAV-GN患者长期移植物失败和死亡风险更高,且移植时ANCA状态可能预测免疫事件,硫唑嘌呤维持治疗与排斥和移植物失败增加相关。
要点
- AAV-GN患者肾移植后短期结局与对照相似,但长期移植物失败和死亡风险更高。
- 移植时ANCA阳性可能提示更高的复发风险,但可能降低排斥风险。
- 硫唑嘌呤维持治疗与更高的排斥和移植物失败风险相关,应避免使用。
核心结论
- AAV-GN患者肾移植后短期结局与对照相似,但长期移植物失败和死亡风险更高。
- 移植时ANCA状态可能有助于预测免疫事件,需仔细评估和监测,但不应延迟移植。
- 硫唑嘌呤应避免作为AAV-GN患者的维持治疗。
研究设计与样本
- 多中心回顾性研究,纳入2005至2023年间法国12个移植中心的206例AAV-GN成人患者和412例匹配对照。
- 比较两组延迟移植物功能、移植物失败、AAV复发、急性排斥和死亡率,并使用多变量模型分析危险因素。
主要发现
- 延迟移植物功能发生率和移植后5年内肾功能两组相似。
- AAV-GN组移植物存活有更差趋势(HR=1.55,P=0.077),总生存率显著更低(HR=1.48,P=0.034)。
- 15例AAV-GN患者(7.3%)发生AAV复发,显著影响移植物存活(P=0.008)。
- 移植时ANCA阳性与更高复发风险趋势相关(HR=4.17,P=0.065),与更低排斥风险相关(HR=0.31,P=0.016)。
- 硫唑嘌呤维持治疗与排斥增加(HR=3.733,P=0.012)和移植物失败增加(HR=3.73,P=0.007<0.001)相关。
临床怎么用
- AAV-GN患者可接受肾移植,但需认识到长期移植物失败和死亡风险较高。
- 移植时评估ANCA状态有助于风险分层,但不应因此延迟移植。
- 避免使用硫唑嘌呤作为维持治疗,选择其他免疫抑制方案。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 样本量有限,部分结果仅为趋势(如移植物存活P=0.077)。
- 未报告具体移植时机与结局的关联,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antineutrophil cytoplasmic autoantibody (ANCA)-associated renal vasculitis (AAV) glomerulonephritis (GN) (AAV-GN) frequently leads to end-stage kidney disease (ESKD). Optimal management for patients with AAV-GN receiving a kidney transplantation (KT) remains poorly characterized. We compared posttransplant outcomes between patients with AAV-GN and controls in the modern era of immunosuppressive therapy. METHODS: This multicenter retrospective study included 206 adult patients with AAV-GN and 412 matched controls who underwent KT between 2005 and 2023 in 12 French transplant centers. We compared the incidence of delayed graft function (DGF), graft failure, AAV relapses, acute rejection, and mortality between groups; and analyzed risk factors using multivariable models. RESULTS: DGF incidence and kidney function up to 5 years after KT were similar between groups. Patients with AAV-GN showed a trend toward poorer graft survival (hazard ratio [HR] = 1.55, P = 0.077) and significantly lower overall survival (HR = 1.48, P = 0.034). AAV relapses occurred in 15 patients with AAV-GN (7.3%), significantly impacting graft survival (P = 0.008). ANCA positivity at KT tended to be associated with higher relapse risk (HR = 4.17, P = 0.065) and was associated with lower rejection risk (HR = 0.31, P = 0.016). Acute rejection incidence was comparable between groups. Azathioprine (AZA) maintenance therapy was associated with increased rejection (HR = 3.733, P = 0.012) and graft failure (HR = 3.73, P = 0.007 < 0.001). Although patients with AAV-GN were waitlisted later than controls, no specific transplant timing was associated with improved outcomes. CONCLUSION: Although KT offers patients with AAV-GN short-term outcomes similar to controls, they face higher long-term risk of graft failure and mortality. ANCA status at transplantation may help predict immunological events, emphasizing the need for careful evaluation and monitoring, but without delaying the process. As for other nephropathies, AZA should be avoided as maintenance therapy in patients with AAV-GN. These findings highlight the need for tailored posttransplant management in patients with AAV-GN.
引用
- Dekervel M, Traversat P, Gatault P, et al. Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis. Kidney Int Rep. 2025. PMID: 41141529. doi:10.1016/j.ekir.2025.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。